A total of 109 patients, 57 men and 52 women treated by 13 gastroenterologists, were included in the study. The median age was 42.5 years (range 18 to 79 years). Patient demographic characteristics, including previous and current medical and surgical therapy, and concomitant medical treatment are summarized in Table 1. Indications for infliximab therapy were inflammatory Crohn’s disease (54 patients [50%]), Crohn’s fistulae (38 patients [35%]), and both inflammatory and fistulizing Crohn’s disease (17 patients [16%]). The median follow-up was 24 weeks (range six to 88 weeks). Efficient treatment has got less costly: find at best online pharmacy.
Demographics and characteristics of patients with inflammatory and/or fistulizing Crohn’s disease who were treated with infusions of infliximab
|Mean age, years (range)||39.2 (18-79)|
|Mean duration of disease, years (range)||12.4 (1-31)|
|Extraintestinal manifestations (n)||11/109|
|Previous total parenteral nutrition therapy (n)||8/109|
|Previous surgery for Crohn’s disease (n)||75/109|
|Small bowel only (n)||25/109|
|Colon only (n)||14/109|
|Small bowel and colon (n)||70/109|
|Indication for infliximab|
|Inflammatory only (n)||54/109|
|Fistulae only (n)||38/109|
|Inflammatory and fistulae (n)||17/109|
Treatment with infliximab
Patients received between one and nine infusions of infliximab 5 mg/kg. Patients with fistulizing disease received three doses of infliximab over six weeks as induction therapy. Forty-three of the 80 patients who initially responded were retreated with additional doses of infliximab for maintenance of remission. The majority of infliximab infusions (98%) were administered in an outpatient setting.